MedPath

A Study of Silodosin 8 mg Daily for the Treatment of Nocturia in Men With Benign Prostatic Hyperplasia

Phase 2
Completed
Conditions
Nocturia
Prostatic Hyperplasia
Interventions
Registration Number
NCT00793819
Lead Sponsor
Watson Pharmaceuticals
Brief Summary

Silodosin is compared to placebo to determine if it is safe and effective for the treatment of nighttime urination (nocturia) in men with BPH

Detailed Description

This will be a multi-center, double-blind, placebo controlled, parallel, 12 week treatment trial in men with signs and symptoms of benign prostatic hyperplasia and nocturia. The following procedures are utilized; physical exams, electrocardiograms, clinical laboratory tests, vital signs, urinary diary, Pittsburgh Quality of Sleep Index, Nocturia Quality of Life

Recruitment & Eligibility

Status
COMPLETED
Sex
Male
Target Recruitment
215
Inclusion Criteria
  • Males in good general health and at least 50 years of age, with symptoms of moderate to severe BPH and nocturia (>=2 episodes per night)
Exclusion Criteria
  • Medical conditions that would confound the efficacy evaluation.
  • Medical conditions in which it would be unsafe to use an alpha-blocker.
  • The use of concomitant drugs that would confound the efficacy evaluation.
  • The use of concomitant drugs that would be unsafe with this alpha-blocker.

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
1 Silodosinsilodosin-
2 Placebosilodosin-
Primary Outcome Measures
NameTimeMethod
Change in Nocturia Episodes12 weeks
Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (1)

Watson Investigational Site

🇺🇸

Burien, Washington, United States

© Copyright 2025. All Rights Reserved by MedPath